CZ286066B6 - Způsob přípravy krystalického Lys B28 Pro B29-lidského inzulínu - Google Patents

Způsob přípravy krystalického Lys B28 Pro B29-lidského inzulínu Download PDF

Info

Publication number
CZ286066B6
CZ286066B6 CZ19951541A CZ154195A CZ286066B6 CZ 286066 B6 CZ286066 B6 CZ 286066B6 CZ 19951541 A CZ19951541 A CZ 19951541A CZ 154195 A CZ154195 A CZ 154195A CZ 286066 B6 CZ286066 B6 CZ 286066B6
Authority
CZ
Czechia
Prior art keywords
lys
pro
human insulin
solution
insulin
Prior art date
Application number
CZ19951541A
Other languages
Czech (cs)
English (en)
Other versions
CZ154195A3 (en
Inventor
Jeffrey Clayton Baker
Nancy Delores Carter
Bruce Hill Frank
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ286066(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CZ154195A3 publication Critical patent/CZ154195A3/cs
Publication of CZ286066B6 publication Critical patent/CZ286066B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CZ19951541A 1994-06-16 1995-06-14 Způsob přípravy krystalického Lys B28 Pro B29-lidského inzulínu CZ286066B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (2)

Publication Number Publication Date
CZ154195A3 CZ154195A3 (en) 1996-02-14
CZ286066B6 true CZ286066B6 (cs) 2000-01-12

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19951541A CZ286066B6 (cs) 1994-06-16 1995-06-14 Způsob přípravy krystalického Lys B28 Pro B29-lidského inzulínu

Country Status (29)

Country Link
US (1) US5504188A (Direct)
EP (1) EP0692489B1 (Direct)
JP (1) JP3595607B2 (Direct)
KR (1) KR100369951B1 (Direct)
CN (1) CN1184234C (Direct)
AT (1) ATE233278T1 (Direct)
AU (1) AU697794B2 (Direct)
BR (1) BR9502798A (Direct)
CA (1) CA2151563C (Direct)
CO (1) CO4410205A1 (Direct)
CZ (1) CZ286066B6 (Direct)
DE (1) DE69529708T2 (Direct)
DK (1) DK0692489T3 (Direct)
ES (1) ES2188637T3 (Direct)
FI (1) FI952930L (Direct)
HU (1) HUT73495A (Direct)
IL (1) IL114152A (Direct)
IN (1) IN178919B (Direct)
MY (1) MY130551A (Direct)
NO (1) NO952334L (Direct)
NZ (1) NZ272358A (Direct)
PE (1) PE21896A1 (Direct)
PL (1) PL180968B1 (Direct)
RO (1) RO113529B1 (Direct)
RU (1) RU2156257C2 (Direct)
SI (1) SI0692489T1 (Direct)
TW (1) TW379228B (Direct)
YU (1) YU39595A (Direct)
ZA (1) ZA954942B (Direct)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
JP2001518915A (ja) * 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
ES2230727T3 (es) * 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
ES2177324T3 (es) * 1998-10-16 2002-12-01 Novo Nordisk As Preparaciones de insulina destinadas a la entrega pulmonar y que contiene mentol.
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DK1121144T3 (da) * 1998-10-16 2002-09-23 Novo Nordisk As Stabile koncentrerede insulinpræparater til pulmonar indgivelse
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
WO2002051428A1 (en) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Sympathetic-activating perfume composition
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
JP5558655B2 (ja) 2003-11-20 2014-07-23 ノヴォ ノルディスク アー／エス 注入デバイスにおける生成および使用に最適なプロピレングリコール含有ペプチド処方
UA91512C2 (ru) 2004-07-19 2010-08-10 Биокон Лимитед Коньюгати олигомеров инсулина, их композиция (варианты) и применение
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
ATE536344T1 (de) 2005-07-04 2011-12-15 High Point Pharmaceuticals Llc Histamine h3 receptor antagonisten
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
CA2629223C (en) 2005-11-17 2013-08-06 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US20090054305A1 (en) 2006-03-15 2009-02-26 Novo Nordisk A/S Mixtures of Amylin and Insulin
SG170785A1 (en) 2006-03-28 2011-05-30 Transtech Pharma Benzothiazoles having histamine h3 receptor activity
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
PL2049475T3 (pl) 2006-04-24 2012-08-31 Lilly Co Eli Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1
HRP20120227T1 (hr) 2006-05-29 2012-04-30 High Point Pharmaceuticals 3-(1,3-benzodioksol-5-il)-6-(4-ciklopropilpiperazin-1-il)piridazin, njegove soli i solvati te njegova uporaba kao antagonista histaminskog h3 receptora
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20100190706A1 (en) 2007-06-01 2010-07-29 Novo Nordisk A/S Stable Non-Aqueous Pharmaceutical Compositions
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
CN101677947B (zh) * 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
MX2010003979A (es) * 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
AU2009316802B2 (en) 2008-11-21 2015-02-26 Vtv Therapeutics Llc Adamantyl benzamide compounds
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND ITS USE
CA2932926C (en) 2009-01-28 2018-12-18 Smartcells, Inc. Conjugate based systems for controlled drug delivery
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US20120178900A1 (en) * 2009-08-11 2012-07-12 Biocon Limited Chromatographic processes and purified compounds thereof
JP6110312B2 (ja) 2011-02-01 2017-04-05 ノヴォ ノルディスク アー／エス インスリンの精製
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
WO2015084694A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
CA3173417A1 (en) 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
IL302775A (en) 2020-11-19 2023-07-01 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
JP2025521112A (ja) 2022-05-18 2025-07-08 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及び関連するインスリン類似体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE515508A (Direct) *
BE533298A (Direct) *
BE533252A (Direct) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
ATE93238T1 (de) * 1988-07-20 1993-09-15 Novo Nordisk As Menschliche insulinanalage und zubereitungen daraus.
WO1990007522A1 (en) * 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DK0792290T3 (da) * 1993-09-17 2001-10-01 Novo Nordisk As Acyleret insulin
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas

Also Published As

Publication number Publication date
FI952930A7 (fi) 1995-12-17
FI952930A0 (fi) 1995-06-14
YU39595A (sh) 1997-08-22
CN1184234C (zh) 2005-01-12
ES2188637T3 (es) 2003-07-01
MY130551A (en) 2007-06-29
FI952930L (fi) 1995-12-17
KR960000922A (ko) 1996-01-25
RU2156257C2 (ru) 2000-09-20
IL114152A0 (en) 1995-10-31
ATE233278T1 (de) 2003-03-15
AU2168195A (en) 1996-01-04
DK0692489T3 (da) 2003-03-31
PL309099A1 (en) 1995-12-27
CN1128271A (zh) 1996-08-07
AU697794B2 (en) 1998-10-15
PE21896A1 (es) 1996-06-15
HUT73495A (en) 1996-08-28
NO952334L (no) 1995-12-18
CA2151563A1 (en) 1995-12-17
DE69529708D1 (de) 2003-04-03
ZA954942B (en) 1996-12-17
CA2151563C (en) 2007-08-07
TW379228B (en) 2000-01-11
RO113529B1 (ro) 1998-08-28
JPH08169899A (ja) 1996-07-02
CO4410205A1 (es) 1997-01-09
IL114152A (en) 1999-12-31
IN178919B (Direct) 1997-07-19
RU95110107A (ru) 1997-05-10
JP3595607B2 (ja) 2004-12-02
DE69529708T2 (de) 2003-10-16
EP0692489B1 (en) 2003-02-26
HU9501715D0 (en) 1995-08-28
CZ154195A3 (en) 1996-02-14
KR100369951B1 (ko) 2003-03-28
BR9502798A (pt) 1996-06-04
SI0692489T1 (en) 2003-06-30
NZ272358A (en) 1996-12-20
PL180968B1 (pl) 2001-05-31
NO952334D0 (no) 1995-06-13
US5504188A (en) 1996-04-02
EP0692489A1 (en) 1996-01-17

Similar Documents

Publication Publication Date Title
CZ286066B6 (cs) Způsob přípravy krystalického Lys B28 Pro B29-lidského inzulínu
NL1004643C2 (nl) Werkwijze voor het bereiden van kristallen van AspB28-menselijk insuline en protamine en deze kristallen bevattende farmaceutische formuleringen.
US5952297A (en) Monomeric insulin analog formulations
US5008241A (en) Novel insulin peptides
EP0254516B1 (en) Novel Peptides
RU2135205C1 (ru) Инсулиновый препарат, способ получения препарата, способ лечения сахарного диабета
EP2708550B1 (en) Preparation method for insulin glargine crystal
EP0216832B1 (en) Novel insulin derivatives and pharmaceutical preparations containing these derivatives
US5597893A (en) Preparation of stable insulin analog crystals
FI98309C (fi) Menetelmä synteettisten isohirudiinien valmistamiseksi, joilla on parantunut stabiilisuus
CN117624335A (zh) 一种门冬胰岛素晶体的制备方法
HK1014006A (en) Preparation of stable zinc insulin analog crystals
EP1539797A1 (en) Process for manufacturing crystals of growth hormone
HK1014008A (en) Preparation of stable insulin analog crystals
AU738101B2 (en) Monomeric insulin analog formulations
HK1014005A (en) Monomeric insulin analog formulations

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20020614